Celltrion gets green light to sell Truxima in Australia

Home > Business > Industry

print dictionary print

Celltrion gets green light to sell Truxima in Australia

Celltrion said Friday it has won approval from an Australian regulator for the sale of its biosimilar drug Truxima.

The Therapeutic Goods Administration accepted Celltrion’s application to sell the biosimilar to Roche’s MabThera, the company said. The antibody biosimilar is used in the treatment of a number of diseases, including rheumatoid arthritis and non-Hodgkin’s lymphoma, a type of leukemia.

With the approval, Truxima would be Celltrion’s second drug, after Remsima, to hit the Australian market, company sources said.


More in Industry

Booze boom

Move over Federer

Hanjin KAL slams largest shareholder, accusing it of peddling lies

Tech firms brief president on state of AI research

Dongsuh recognizes female authors at Scent of Life Awards

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now